<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interferon alfa-2b (United States and Canada: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interferon alfa-2b (United States and Canada: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Interferon alfa-2b (United States and Canada: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10764" href="/d/html/10764.html" rel="external">see "Interferon alfa-2b (United States and Canada: Not available): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13384" href="/d/html/13384.html" rel="external">see "Interferon alfa-2b (United States and Canada: Not available): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708923"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric, autoimmune, ischemic, and infectious disorders:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Alpha interferons, including interferon alfa-2b, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases, these disorders resolve after stopping interferon alfa-2b therapy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F183204"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Intron A [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867211"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Intron A (Hsa-Free) [DSC];</li>
<li>Intron A [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F183227"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Biological Response Modulator;</li>
<li>
                        Biological Response Modulator;</li>
<li>
                        Interferon</li></ul></div>
<div class="block doa drugH1Div" id="F183207"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Consider premedication with acetaminophen prior to administration to reduce the incidence of some adverse reactions. Not all dosage forms and strengths are appropriate for all indications; refer to product labeling for details. Interferon alfa-2b at doses ≥10 million units/m<sup>2</sup> is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a881e1b5-4635-4167-8c83-7c4811057163">Adult T-cell leukemia/lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adult T-cell leukemia/lymphoma (off-label use): SubQ:</b> 5 million units once daily (in combination with zidovudine); if interferon is tolerated, may escalate dose after 1 week to 10 million units once daily; continue until at least 4 weeks after achieving a complete remission or for 1 year in the absence of a complete remission (Gill 1995) <b>or</b> 3 to 5 million units once daily or once every other day (in combination with zidovudine), may escalate dose if well tolerated (Matutes 2001) <b>or</b> 5 million units once daily (in combination with zidovudine and arsenic trioxide) (Kchour 2009). Refer to protocol(s) for dosage adjustment recommendations.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="105cec0a-a7ca-40e2-861c-ca22d0bd524f">AIDS-related Kaposi sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>AIDS-related Kaposi sarcoma: IM, SubQ:</b> 30 million units/m<sup>2</sup> 3 times a week; continue until disease progression or until maximal response has been achieved after 16 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>O</i>
<i>ff-label dosing:</i>
<b>SubQ:</b> 8 million units once daily in the evening (in combination with zidovudine) until disease progression or for a maximum of 1 year (Shepherd 1998). Refer to protocol for dosage adjustment recommendations.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff6e1a22-9463-46c0-8867-6c9544232546">Behçet syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Behçet syndrome (mucocutaneous ulcers) (off-label use; based on limited data): SubQ:</b> 5 million units 3 times/week for 6 weeks, followed by 5 million units once a week for 10 weeks (Hamuryudan 1994). The optimal dose, frequency, and duration of interferon alfa-2b therapy for management of Behçet syndrome is unclear; dosing from case reports and small studies is variable (ranging from ~2 to 5 million units/dose) (Kötter 2004).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9203ca82-591f-48b9-85f3-5262945663e6">Chronic hepatitis B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis B (alternative therapy [WHO 2015]):</b>
<b>IM, SubQ:</b> 5 million units once daily or 10 million units 3 times a week for 16 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e83a9ca3-b3aa-43a7-87a1-d31422513194">Chronic myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia (alternate therapy in patients unable to take tyrosine kinase inhibitors) (off-label use; based on limited data): SubQ:</b> 3 million units once daily; if needed (based on WBC counts), may increase to 6 million units once daily (Kuroiwa 1998) <b>or</b> 4 million units 5 days/week (Lipton 1996).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f7768d9-fe10-45d3-adfe-fec61d8cd8c8">Condyloma acuminata</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Condyloma acuminata:</b>
<b>Intralesional:</b> 1 million units/lesion (maximum: 5 lesions per treatment) 3 times a week (on alternate days) for 3 weeks. May administer a second course at 12 to 16 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8035241d-374a-4148-bdb4-e510984c4460">Cutaneous T-cell lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous T-cell lymphomas (mycosis fungoides/<b>Sézary syndrome) (off-label use): </b></b>
<i>Early stage disease (in combination with psoralen and ultraviolet A therapy [PUVA]): </i>
<b>SubQ:</b> 1.5 million units once daily during week 1, followed by 3 million units once daily during week 2, followed by 6 million units 3 times/week during week 3 (on the day prior to PUVA) until complete response or for a maximum of 2 months, then maintenance therapy of 3 million units 3 times/week for 2 months followed by 3 million units 2 times/week for 10 months (Rupoli 2005).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1185fba-fdcb-4ec5-9365-ade7ff73a22c">Desmoid tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Desmoid tumors (off-label use; based on limited data [dosing extrapolated from interferon alfa-2c]): SubQ:</b> 3.5 million units 3 times/week (with or without tretinoin) until disease progression or unacceptable toxicity (Leithner 2000).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49e556fc-5a6b-49cb-9bbe-bc6a18f07186">Essential thrombocythemia, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Essential thrombocythemia, advanced (off-label use): SubQ:</b> 3 million units 3 times a week for 2 years, followed by 5 million units twice a week (Huang 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6809a202-6933-4fe2-a689-981abd6e2a63">Hairy cell leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hairy cell leukemia:</b>
<b>IM, SubQ:</b> 2 million units/m<sup>2</sup> 3 times a week for up to 6 months (may continue treatment with sustained treatment response); discontinue for disease progression or failure to respond after 6 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8c639df-196b-419f-a269-30e3cd8c627c">Lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphoma (follicular):</b>
<b>SubQ:</b> 5 million units 3 times a week for up to 18 months (initially in combination with an anthracycline-containing combination chemotherapy regimen, and then as monotherapy after completion of the chemotherapy regimen).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0390764b-f4a1-48b7-bffe-fe1ea11154f2">Melanoma, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma (malignant), adjuvant therapy (alternative therapy):</b> Induction: 20 million units/m<sup>2</sup> IV for 5 consecutive days per week for 4 weeks, followed by maintenance dosing of 10 million units/m<sup>2</sup> SUBQ 3 times a week for 48 weeks. <b>Note:</b> High-dose interferon no longer has a defined role in the adjuvant treatment of cutaneous melanoma and is not recommended for routine adjuvant use (ASCO [Seth 2020]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dbd54e47-8d9c-4d17-9ace-a69bd55195e5">Myelofibrosis, early</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelofibrosis, early (off-label use): SubQ:</b> 0.5 to 1 million units 3 times a week, gradually increasing to 2 to 3 million units 3 times a week as tolerated (Silver 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c88192d3-83f5-4af3-a1f9-9326746db49a">Neuroendocrine tumors, gastrointestinal carcinoid tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumors, gastrointestinal carcinoid tumors (alternate therapy) (off-label use; based on limited data): SubQ:</b> 3 to 5 million units 3 times a week (Oberg 2003; Pavel 2013) <b>or</b> 5 million units (median dose) every other day (range: 3 to 9 million units once daily or every other day), titrate to a dose that maintains leukocyte count &lt;3,000/mm<sup>3</sup> (Oberg 2003).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ffadc97-530e-4d92-ae50-84704ada33f8">Peyronie disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peyronie disease (off-label use): Intralesional:</b> 5 million units (in 10 mL NS) every other week for a total of 6 doses (Hellstrom 2006) <b>or</b> 2 million units (in 10 mL NS) every other week for a median of 12 injections (Stewart 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6367ffd-86e3-4bc9-ad9a-e45bb012e46d">Polycythemia vera, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polycythemia vera, advanced (off-</b>
<b>label use):</b>
<b>SubQ:</b> 3 million units 3 times a week for 2 years, followed by 5 million units twice a week (Huang 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eb6d48e5-2013-40a7-9bad-cb92e95a8121">West Nile virus, neurologic symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>West Nile virus, neurologic symptoms (off-label use; based on limited data): SubQ:</b> 3 million units once daily for 14 days (Kalil 2005; Sayao 2004).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990479"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal impairment at treatment initiation:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal toxicity during treatment:</b>
<i>Indication-specific adjustment:</i> Lymphoma (follicular): Serum creatinine &gt;2 mg/dL: Permanently discontinue.</p></div>
<div class="block doha drugH1Div" id="F50987760"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at treatment initiation: </b>There are no dosage adjustments provided in the manufacturer's labeling. Contraindicated in patients with decompensated liver disease or autoimmune hepatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment: </b> Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Indication-specific adjustments: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Lymphoma (follicular): AST &gt;5 times ULN: Permanently discontinue.</p>
<p style="text-indent:-2em;margin-left:6em;">Melanoma, malignant (induction and maintenance):</p>
<p style="text-indent:-2em;margin-left:8em;">ALT/AST &gt;5 to 10 times ULN: Temporarily withhold; resume with a 50% dose reduction when adverse reaction abates</p>
<p style="text-indent:-2em;margin-left:8em;">ALT/AST &gt;10 times ULN: Permanently discontinue.</p></div>
<div class="block dot drugH1Div" id="F183228"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hematologic toxicity (also refer to indication specified adjustments below): ANC &lt;500/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reaction (acute, serious), ophthalmic disorders (new or worsening), thyroid abnormality development (which cannot be normalized with medication), signs or symptoms of liver failure: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Liver function abnormality, pulmonary infiltrate development, evidence of pulmonary function impairment, or autoimmune disorder development, triglycerides &gt;1,000 mg/dL: Monitor closely and discontinue if appropriate. Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>
<p style="text-indent:-2em;margin-left:2em;">Neuropsychiatric disorders (during treatment):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Clinical depression or other psychiatric problem:</i> Monitor closely during and for 6 months after treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe depression or other psychiatric disorder:</i> Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Persistent or worsening psychiatric symptoms, suicidal ideation, aggression towards others:</i> Discontinue treatment and follow with appropriate psychiatric intervention.</p>
<p style="text-indent:-2em;margin-left:2em;">Manufacturer-recommended adjustments, listed according to indication:</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Lymphoma (follicular): </i></p>
<p style="text-indent:-2em;margin-left:4em;">Neutrophils &gt;1000/mm<sup>3</sup> to &lt;1,500/mm<sup>3</sup>: Reduce dose by 50%; may re-escalate to starting dose when neutrophils return to &gt;1,500/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Severe toxicity (neutrophils &lt;1000/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>): Temporarily withhold.</p>
<p style="text-indent:-2em;margin-left:4em;">AST &gt;5 times ULN or serum creatinine &gt;2 mg/dL: Permanently discontinue.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hairy cell leukemia:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Platelet count &lt;50,000/mm<sup>3</sup>: Do not administer intramuscularly (administer SubQ instead).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe toxicity: Reduce dose by 50% or temporarily withhold and resume with 50% dose reduction; permanently discontinue if persistent or recurrent severe toxicity is noted.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Chronic hepatitis B</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">WBC &lt;1,500/mm<sup>3</sup>, granulocytes &lt;750/mm<sup>3</sup>, or platelet count &lt;50,000/mm<sup>3</sup>, or other laboratory abnormality or severe adverse reaction: Reduce dose by 50%; may re-escalate to starting dose upon resolution of hematologic toxicity. Discontinue for persistent intolerance.</p>
<p style="text-indent:-2em;margin-left:4em;">WBC &lt;1,000/mm<sup>3</sup>, granulocytes &lt;500/mm<sup>3</sup>, or platelet count &lt;25,000/mm<sup>3</sup>: Permanently discontinue</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>AIDS-related Kaposi sarcoma:</i> Severe toxicity: Reduce dose by 50% or temporarily withhold; may resume at reduced dose with toxicity resolution; permanently discontinue for persistent/recurrent toxicities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Melanoma, malignant (induction and maintenance): </i></p>
<p style="text-indent:-2em;margin-left:4em;">Severe toxicity including neutrophils &gt;250/mm<sup>3</sup> to &lt;500/mm<sup>3</sup> or ALT/AST &gt;5 to 10 times ULN: Temporarily withhold; resume with a 50% dose reduction when adverse reaction abates.</p>
<p style="text-indent:-2em;margin-left:4em;">Neutrophils &lt;250/mm<sup>3</sup>, ALT/AST &gt;10 times ULN, or severe/persistent adverse reactions: Permanently discontinue.</p></div>
<div class="block doe drugH1Div" id="F183208"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F183218"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13384" href="/d/html/13384.html" rel="external">see "Interferon alfa-2b (United States and Canada: Not available): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consider premedication with acetaminophen to reduce the incidence of some adverse reactions. Not all dosage forms and strengths are appropriate for all indications; refer to product labeling for details.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9203ca82-591f-48b9-85f3-5262945663e6">Chronic hepatitis B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis B:</b> Children and Adolescents: SubQ: 3 million units/m<sup>2</sup>/dose 3 times per week for 1 week; then 6 million units/m<sup>2</sup>/dose 3 times per week; maximum dose: 10 million units/dose; total duration of therapy is 16 to 24 weeks. <b>Note:</b> In HIV-exposed/-infected patients, higher doses may be used for retreatment of failed lower-dose therapy: 10 million units/m<sup>2</sup>/dose 3 times per week for 6 months (HHS [OI pediatric 2016]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16cca722-a1a6-4d17-8ffa-869e415681a6">Chronic hepatitis C</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis C: </b>
<b>Note: </b>Interferon-free therapies are generally preferred in the treatment of hepatitis C (AASLD/IDSA 2017; WHO 2016): Children ≥3 years and Adolescents: IM, SubQ: 3 million units/m<sup>2</sup>/dose 3 times per week in combination with ribavirin</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic toxicity (also refer to indication specified adjustments below):</i> Children and Adolescents: ANC &lt;500/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hypersensitivity reaction (acute, serious), ophthalmic disorders (new or worsening), thyroid abnormality development (which cannot be normalized with medication), signs or symptoms of liver failure</i>: Children and Adolescents: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Liver function abnormality, pulmonary infiltrate development, evidence of pulmonary function impairment, or autoimmune disorder development, persistently elevated triglycerides (eg, &gt;1,000 mg/dL in adults):</i> Children and Adolescents: Monitor closely and discontinue if appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neuropsychiatric disorders (during treatment):</i> Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Clinical depression or other psychiatric problem: Monitor closely during and for 6 months after treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe depression or other psychiatric disorder: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Persistent or worsening psychiatric symptoms, suicidal ideation, aggression towards others: Discontinue treatment and follow with appropriate psychiatric intervention.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Indication-specific, manufacturer-recommended adjustments: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Chronic hepatitis B:</b> Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">WBC &lt;1500/mm<sup>3</sup>, granulocytes &lt;750/mm<sup>3</sup>, or platelet count &lt;50,000/mm<sup>3</sup>, or other laboratory abnormality or severe adverse reaction: Reduce dose by 50%; may re-escalate to starting dose upon resolution of hematologic toxicity. Discontinue for persistent intolerance.</p>
<p style="text-indent:-2em;margin-left:8em;">WBC &lt;1000/mm<sup>3</sup>, granulocytes &lt;500/mm<sup>3</sup>, or platelet count &lt;25,000/mm<sup>3</sup>: Permanently discontinue.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hepatitis C, chronic</b>: Children and Adolescents: Severe toxicity: Reduce dose by 50% or temporarily withhold until subsides; permanently discontinue for persistent toxicities after dosage reduction.</p>
<p style="text-indent:-2em;margin-left:6em;">In other oncology uses, the following have been used in adult patients:</p>
<p style="text-indent:-2em;margin-left:8em;">Lymphoma (follicular): Adults:</p>
<p style="text-indent:-2em;margin-left:10em;">Neutrophils &gt;1,000/mm<sup>3</sup> to &lt;1,500/mm<sup>3</sup>: Reduce dose by 50%; may re-escalate to starting dose when neutrophils return to &gt;1,500/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:10em;">Severe toxicity (neutrophils &lt;1,000/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>): Temporarily withhold.</p>
<p style="text-indent:-2em;margin-left:10em;">AST &gt;5 times ULN or serum creatinine &gt;2 mg/dL: Permanently discontinue.</p>
<p style="text-indent:-2em;margin-left:8em;">Hairy cell leukemia: Adults:</p>
<p style="text-indent:-2em;margin-left:10em;">Platelet count &lt;50,000/mm<sup>3</sup>: Do not administer intramuscularly (administer SubQ instead).</p>
<p style="text-indent:-2em;margin-left:10em;">Severe toxicity: Reduce dose by 50% or temporarily withhold and resume with 50% dose reduction; permanently discontinue if persistent or recurrent severe toxicity is noted.</p>
<p style="text-indent:-2em;margin-left:8em;">AIDS-related Kaposi sarcoma: Adults: Severe toxicity: Reduce dose by 50% or temporarily withhold; may resume at reduced dose with toxicity resolution; permanently discontinue for persistent/recurrent toxicities.</p>
<p style="text-indent:-2em;margin-left:8em;">Malignant melanoma (induction and maintenance): Adults:</p>
<p style="text-indent:-2em;margin-left:10em;">Severe toxicity, including neutrophils &gt;250/mm<sup>3</sup> to &lt;500/mm<sup>3</sup> or ALT/AST &gt;5 to 10 times ULN: Temporarily withhold; resume with a 50% dose reduction when adverse reaction abates.</p>
<p style="text-indent:-2em;margin-left:10em;">Neutrophils &lt;250/mm<sup>3</sup>, ALT/AST &gt;10 times ULN, or severe/persistent adverse reactions: Permanently discontinue.</p></div>
<div class="block dorp drugH1Div" id="F51114036"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline renal impairment: Children and Adolescents: Combination therapy with ribavirin (hepatitis C) is contraindicated in patients with CrCl &lt;50 mL/minute; use combination therapy with ribavirin (hepatitis C) with caution in patients with impaired renal function and CrCl ≥50 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Nephrotoxicity during therapy: There are no pediatric specific recommendations; based on experience in adult patients, dosage adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51114037"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Baseline hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling. Contraindicated in patients with decompensated liver disease or autoimmune hepatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity during treatment: Children and Adolescents: Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p></div>
<div class="block adr drugH1Div" id="F183175"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (8% to 96%), headache (21% to 62%), chills (45% to 54%), rigors (2% to 42%), depression (3% to 40%), drowsiness (1% to 33%), dizziness (≤23%), vertigo (≤23%), irritability (≤22%), pain (3% to 18%), right upper quadrant pain (≤15%), malaise (3% to 14%), paresthesia (≤13%), confusion (≤12%), insomnia (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (8% to 38%), skin rash (1% to 25%), diaphoresis (1% to 13%), pruritus (1% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (≤13%), amenorrhea (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (1% to 69%), nausea and vomiting (66%; children: 40%), nausea (17% to 66%), gastrointestinal disease (≤7%; children: 46%), diarrhea (2% to 35%), vomiting (2% to 40%), dysgeusia (≤24%), xerostomia (1% to 22%), abdominal pain (≤20%), constipation (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (≤92%; grades 3/4: 26%; children: 13% to 14%), granulocytopenia (31% to 92%), decreased white blood cell count (9% to 68%), leukopenia (&lt;5%; malignant melanoma, grades 3/4: ≤26%), anemia (≤22%), decreased platelet count (1% to 15%), thrombocytopenia (≤10%; children: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (4% to 63%), increased serum alkaline phosphatase (4% to 13%), increased serum alanine aminotransferase (2% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (≤20%; children: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (16% to 75%), asthenia (≤63%), musculoskeletal pain (1% to 21%), arthralgia (3% to 19%), back pain (1% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (2% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (≤45%; children: 100%), dyspnea (≤15%), cough (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (34% to 94%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (≤9%), chest pain (≤8%; includes substernal), peripheral edema (≤6%), edema (≤5%), peripheral vascular insufficiency (≤5%), angina pectoris (&lt;5%), arteritis (&lt;5%), atrial fibrillation (&lt;5%), bradycardia (&lt;5%), cardiac arrhythmia (&lt;5%), cardiac failure (&lt;5%), cardiomegaly (&lt;5%), cardiomyopathy (&lt;5%), cerebrovascular accident (&lt;5%), coronary artery disease (&lt;5%), extrasystoles (&lt;5%), flushing (&lt;5%), heart valve disease (&lt;5%), hypotension (&lt;5%), orthostatic hypotension (&lt;5%), palpitations (&lt;5%), polyarteritis nodosa (&lt;5%), peripheral ischemia (&lt;5%), phlebitis (&lt;5%), pulmonary embolism (&lt;5%), Raynaud disease (&lt;5%), syncope (&lt;5%), tachycardia (&lt;5%), thrombosis (&lt;5%), varicose veins (&lt;5%), facial edema (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anxiety (≤9%), lack of concentration (≤8), agitation (≤7%), hypothermia (≤5%), abnormal dreams (&lt;5%), abnormal gait (&lt;5%), abnormality in thinking (&lt;5%), aggressive behavior (&lt;5%), altered sense of smell (&lt;5%), amnesia (&lt;5%), apathy (&lt;5%), aphasia (&lt;5%), ataxia (&lt;5%), Bell palsy (&lt;5%), carpal tunnel syndrome (&lt;5%), central nervous system dysfunction (&lt;5%), coma (&lt;5%), delirium (&lt;5%), dysphasia (&lt;5%), emotional lability (&lt;5%), exacerbation of depression (&lt;5%), extrapyramidal reaction (&lt;5%), hyperesthesia (&lt;5%), hyperthermia (&lt;5%), hypertonia (&lt;5%), hypoesthesia (&lt;5%), hyporeflexia (&lt;5%), intoxicated feeling (&lt;5%), loss of consciousness (&lt;5%), manic depressive reaction (&lt;5%), manic reaction (&lt;5%), migraine (&lt;5%), myasthenia (&lt;5%), neuralgia (&lt;5%), neuritis (&lt;5%), neuropathy (&lt;5%), nightmares (&lt;5%), paresis (&lt;5%), personality disorder (&lt;5%), polyneuropathy (&lt;5%), psychoneurosis (&lt;5%), psychosis (&lt;5%), seizure (&lt;5%), speech disturbance (&lt;5%), twitching (&lt;5%), voice disorder (&lt;5%), nervousness (1% to 3%), attempted suicide (≤2%), suicidal ideation (≤2%),</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Xeroderma (≤9%), dermatitis (1% to 8%), injection site pruritus (≤5%), abnormal hair texture (&lt;5%), acne vulgaris (&lt;5%), cellulitis (&lt;5%), cold and clammy skin (&lt;5%), eczema (&lt;5%), epidermal cyst of skin (&lt;5%), erythema (&lt;5%), erythema nodosum (&lt;5%), erythematous rash (&lt;5%), exacerbation of psoriasis (&lt;5%), folliculitis (&lt;5%), furunculosis (&lt;5%), genital pruritus (&lt;5%), lichenoid dermatitis (&lt;5%), maculopapular rash (&lt;5%), nail disease (&lt;5%), pallor (&lt;5%), psoriasis (&lt;5%), skin depigmentation (&lt;5%), skin discoloration (&lt;5%), skin photosensitivity (&lt;5%), toxic epidermal necrolysis (&lt;5%), urticaria (&lt;5%), vitiligo (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Cachexia (≤5%), decreased libido (≤5%), dehydration (≤5%), hypercalcemia (≤5%), hyperglycemia (≤5%), increased thirst (≤5%), weight gain (≤5%), albuminuria (&lt;5%), cutaneous nodule (&lt;5%), exacerbation of diabetes mellitus (&lt;5%), goiter (&lt;5%), gynecomastia (&lt;5%), heavy menstrual bleeding (&lt;5%), hypertrichosis (&lt;5%), hot flash (&lt;5%), hyperthyroidism (&lt;5%), hypertriglyceridemia (&lt;5%), hypothyroidism (&lt;5%), menstrual disease (&lt;5%), increased lactate dehydrogenase (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (2% to 8%), gingivitis (1% to 7%), hernia of abdominal cavity (≤5%), abdominal distention (&lt;5%), ageusia (&lt;5%), aphthous stomatitis (&lt;5%; including non-herpetic cold sore), biliary colic (&lt;5%), cholelithiasis (&lt;5%), colitis (&lt;5%), dental disease (&lt;5%), dysphagia (&lt;5%), eructation (&lt;5%), esophagitis (&lt;5%), flatulence (&lt;5%), gastric ulcer (&lt;5%), gastritis (&lt;5%), gastroenteritis (&lt;5%), gastrointestinal hemorrhage (&lt;5%), gingival hemorrhage (&lt;5%), gingival hyperplasia (&lt;5%), halitosis (&lt;5%), hemorrhoids (&lt;5%), increased appetite (&lt;5%), melanosis (&lt;5%), melena (&lt;5%), mucositis (&lt;5%), oral leukoplakia (&lt;5%), oral mucosa ulcer (&lt;5%), sialorrhea (&lt;5%), stomatitis (&lt;5%), tongue disease (&lt;5%), loose stools (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastitis (≤5%), penile swelling (≤5%), scrotal edema (≤5%), urinary tract infection (≤5%), herpes genitalis (1% to 5%), cystitis (&lt;5%), dysmenorrhea (&lt;5%), dysuria (&lt;5%), hematuria (&lt;5%), impotence (&lt;5%), leukorrhea (&lt;5%), nocturia (&lt;5%), pelvic pain (&lt;5%), penile disease (&lt;5%), proteinuria (&lt;5%), sexual disorder (&lt;5%), urinary frequency (&lt;5%), urinary incontinence (&lt;5%), urination disorder (&lt;5%), uterine hemorrhage (&lt;5%), vaginal dryness (&lt;5%), virilization (&lt;5%), genital candidiasis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenitis (≤5%), lymphadenopathy (≤5%), purpuric rash (≤5%), hematoma (&lt;5%), hemolytic anemia (&lt;5%), hypochromic anemia (&lt;5%), lipoma (&lt;5%), lymphocytosis (&lt;5%), oral hemorrhage (&lt;5%), rectal hemorrhage (&lt;5%), thrombotic thrombocytopenic purpura (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (&lt;5%), ascites (&lt;5%), hepatic encephalopathy (&lt;5%), hepatic failure (&lt;5%), hepatitis (&lt;5%), hyperbilirubinemia (&lt;5%), jaundice (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤5%; includes acute reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (≤7%; including hemophilus), viral infection (7%), abscess (&lt;5%), bacterial infection (&lt;5%), fungal infection (&lt;5%), herpes zoster infection (&lt;5%), parasitic infection (including trichomonas), sepsis (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bleeding at injection site (≤5%), burning sensation at injection site (≤5%), local pain (pleural: ≤5%), pain at injection site (≤5%), inflammation at injection site (1% to 5%), local discoloration (gastrointestinal mucosa: &lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Amyotrophy (&lt;5%), arthritis (&lt;5%), bone disease (&lt;5%), exacerbation of arthritis (&lt;5%), hyperkinesia (&lt;5%), hypokinesia (&lt;5%), lower limb cramp (&lt;5%), ostealgia (&lt;5%), osteoarthritis (&lt;5%), rheumatoid arthritis (&lt;5%), spondylitis (&lt;5%), tendinopathy (&lt;5%), tremor (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Periorbital edema (≤5%), blurred vision (&lt;5%), conjunctivitis (&lt;5%), diplopia (&lt;5%), eye pain (&lt;5%), hordeolum (&lt;5%), lacrimation (&lt;5%), nystagmus (&lt;5%), photophobia (&lt;5%), visual disturbance (&lt;5%), xerophthalmia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (≤5%), auditory impairment (&lt;5%), labyrinth disease (&lt;5%), otitis media (&lt;5%), tinnitus (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (≤10%), increased serum creatinine (2% to 6%), renal insufficiency (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≤10%), pharyngitis (≤8%), epistaxis (≤7%), nasal congestion (≤7%), asthma (≤5%), bronchospasm (≤5%), cyanosis (≤5%), hemoptysis (≤5%), hypoventilation (≤5%), laryngitis (≤5%), orthopnea (≤5%), pleural effusion (≤5%), pneumonia (≤5%), pneumonitis (≤5%), pneumothorax (≤5%), pulmonary fibrosis (≤5%), rales (≤5%), respiratory insufficiency (≤5%), respiratory tract disease (≤5%), sneezing (≤5%), tonsillitis (≤5%), tracheitis (≤5%), wheezing (≤5%), rhinitis (&lt;5%), rhinorrhea (&lt;5%), upper respiratory tract infection (&lt;5%), sinusitis (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Inflammation (≤5%), alcohol intolerance (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, aplastic anemia, autoimmune disease, bronchoconstriction, encephalopathy, erythema multiforme, exacerbation of sarcoidosis, hallucination, hepatotoxicity, homicidal ideation, immune thrombocytopenia, ischemic changes (cerebrovascular events), leukemia (intralesional administration), macular edema, myocardial infarction, myositis, nephrotic syndrome, optic neuritis, pancreatitis, pancytopenia, pericarditis, peripheral neuropathy, pituitary insufficiency, pulmonary hypertension, pulmonary infiltrates, pure red cell aplasia, reactivation of HBV, reduced ejection fraction, renal failure syndrome, retinal detachment (serous), rhabdomyolysis, sarcoidosis, Stevens-Johnson syndrome, suicidal tendencies, supraventricular cardiac arrhythmia, systemic lupus erythematosus, tissue necrosis at injection site, tongue discoloration, vasculitis, Vogt-Koyanagi-Harada syndrome</p></div>
<div class="block coi drugH1Div" id="F183189"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to interferon alfa or any component of the formulation; decompensated liver disease; autoimmune hepatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Combination therapy with interferon alfa-2b and ribavirin is also contraindicated in females who are pregnant, in males whose female partners are pregnant; in patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia); CrCl &lt;50 mL/minute; or hypersensitivity to ribavirin or any ribavirin component.</p></div>
<div class="block war drugH1Div" id="F183172"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Interferon alfa-2b causes bone marrow suppression, including potentially severe cytopenias, and, very rarely, aplastic anemia. Discontinue treatment for severe neutropenia (ANC &lt;500/mm<sup>3</sup>) or thrombocytopenia (platelets &lt;25,000/mm<sup>3</sup>). Hemolytic anemia (hemoglobin &lt;10 g/dL) was observed in ~10% of treated patients in clinical trials when combined with ribavirin; anemia occurred within 1 to 2 weeks of initiation of therapy. Use caution in patients with preexisting myelosuppression and in patients with concomitant medications which cause myelosuppression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular events: Hemorrhagic and ischemic cerebrovascular events have been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dental and periodontal disorders: In patients receiving combination interferon and ribavirin therapy, dental and periodontal disorders have been reported; additionally, dry mouth can damage teeth and mouth mucous membranes during chronic therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Flu-like symptoms: Interferon alfa-2b is commonly associated with fever and flu-like symptoms; rule out other causes/infections with persistent fever. Use with caution in patients with debilitating conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Antiemetics may be recommended to prevent nausea and vomiting; interferon alfa-2b doses of 15 to 30 million units/m<sup>2</sup>/day IV are associated with a moderate emetic potential in pediatrics (POGO [Paw Cho Sing 2019]), and doses ≥10 million units/m<sup>2</sup> are associated with a moderate emetic potential in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Interferon alfa-2b may cause hepatotoxicity (including fatality); monitor closely if abnormal LFTs develop. A transient increase in ALT (≥2 times baseline) may occur in patients treated with interferon alfa-2b for chronic hepatitis B. Therapy generally may continue, however, functional indicators (eg, albumin, prothrombin time, bilirubin) should be monitored frequently. Worsening and potentially fatal liver disease, including jaundice, hepatic encephalopathy, and hepatic failure, have been reported in patients receiving interferon alfa for chronic hepatitis B and C with decompensated liver disease, autoimmune hepatitis, history of autoimmune disease, and immunosuppressed transplant recipients; avoid interferon treatment (if appropriate) in these patients (use is contraindicated in decompensated liver disease). Patients with cirrhosis are at increased risk of hepatic decompensation. Therapy should be discontinued for any patient developing signs and symptoms of liver failure. Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B virus reactivation: The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antibody to hepatitis B surface antigen (anti-HBs) prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) have been reported (rarely) with alfa interferons. If an acute reaction develops, discontinue therapy immediately; transient rashes have occurred in some patients following injection, but have not necessitated treatment interruption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertriglyceridemia: Elevated triglycerides have been reported (discontinue if persistent and severe, particularly if combined with symptoms of pancreatitis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric disorders: <b>[US Boxed Warning]: May cause or aggravate severe neuropsychiatric adverse events; monitor closely with clinical evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b> Psychiatric events may include depression psychosis, mania, suicidal ideation, suicide attempts, completed suicides, and homicidal ideation; may occur in patients with or without previous psychiatric symptoms. Effects are usually rapidly reversible upon therapy discontinuation, but have persisted up to 3 weeks. If psychiatric symptoms persist or worsen, or suicidal or homicidal ideation or aggressive behavior towards others is identified, discontinue treatment and follow the patient closely. Careful neuropsychiatric monitoring is recommended during and for 6 months after treatment in patients who develop psychiatric disorders (including clinical depression). New or exacerbated neuropsychiatric or substance abuse disorders are best managed with early intervention. Use with caution in patients with a history of psychiatric disorders. Drug screening and periodic health evaluation (including monitoring of psychiatric symptoms) is recommended if initiating treatment in patients with coexisting psychiatric condition or substance abuse disorders. Suicidal ideation or attempts may occur more frequently in pediatric patients (eg, adolescents) when compared to adults. Higher doses, usually in patients ≥65 years of age, may result in increased CNS toxicity (eg, obtundation and coma).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Decreased or loss of vision, macular edema, optic neuritis, retinal hemorrhages, cotton wool spots, papilledema, retinal detachment (serous), and retinal artery or vein thrombosis have occurred (or been aggravated) in patients receiving alfa interferons. Use caution in patients with preexisting eye disorders; monitor closely; a complete eye exam should be done promptly in patients who develop ocular symptoms; discontinue with new or worsening ophthalmic disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary effects: Dyspnea, pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis, pneumonia, bronchiolitis obliterans, and sarcoidosis may be induced or aggravated by treatment, sometimes resulting in respiratory failure or fatality. Has been reported more in patients who were treated for chronic hepatitis C, although has also occurred with use for oncology indications. Patients with fever, cough, dyspnea or other respiratory symptoms should be evaluated with a chest x-ray; monitor closely and consider discontinuing treatment with evidence of impaired pulmonary function. Use with caution in patients with a history of pulmonary disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• AIDS-related Kaposi sarcoma: Do not treat patients with visceral AIDS-related Kaposi sarcoma associated with rapidly-progressing or life-threatening disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disease: <b>[US Boxed Warning]: May cause or aggravate fatal or life-threatening autoimmune disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation. </b> Autoimmune disorders (thrombocytopenia, vasculitis, Raynaud disease, rheumatoid arthritis, lupus erythematosus and rhabdomyolysis) have been associated with alfa interferons. Worsening of psoriasis and sarcoidosis (and the development of new sarcoidosis) have been reported; use caution in patients with these conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease; monitor closely in patients with cardiovascular disease (ischemic or thromboembolic), arrhythmias, hypertension, and in patients with a history of MI and/or prior therapy with cardiotoxic drugs. Patients with preexisting cardiac disease and/or advanced cancer should have baseline and periodic ECGs. May cause hypotension (during administration or delayed up to 2 days), arrhythmia, tachycardia (≥150 bpm), cardiomyopathy (~2% in patients with AIDS-related Kaposi sarcoma), and/or myocardial infarction (MI); some experiencing cardiovascular adverse effects had no prior history of cardiac disease. Supraventricular arrhythmias occur rarely and are associated with preexisting cardiac disease or prior therapy with cardiotoxic agents. Dose modification, discontinuation and/or additional therapies may be necessary. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic hepatitis: Patients being treated for chronic hepatitis B or C with a history of autoimmune disease or who are immunosuppressed transplant recipients should not receive interferon alfa-2b.</p>
<p style="text-indent:-2em;margin-left:4em;">• Coagulation disorders: Use with caution and monitor closely in patients with coagulation disorders (eg, thrombophlebitis, pulmonary embolism).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Diabetes mellitus has been reported; discontinue if diabetes cannot be effectively managed with medication. Use with caution in patients with a history of diabetes mellitus, particularly if prone to DKA.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infectious disorders: <b> [US Boxed Warning]: May cause or aggravate fatal or life-threatening infectious disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ischemic disorders:<b> [US Boxed Warning]: May cause or aggravate fatal or life-threatening ischemic disorders; monitor closely with clinical and laboratory evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary disorders: Use with caution and monitor closely in patients with pulmonary disorders (eg, chronic obstructive pulmonary disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disorders: Use with caution in patients with preexisting thyroid disease; thyroid disorders (hyper- or hypothyroidism) have been reported. Thyroid-stimulating hormone levels should be within normal limits prior to initiating interferon; treatment should not be initiated in patients with preexisting thyroid disease who cannot be maintained in normal ranges by medication. Discontinue interferon use in patients who develop thyroid abnormalities during treatment and in patients with thyroid disease who subsequently cannot maintain normal ranges with thyroid medication. Discontinuation of interferon therapy may or may not reverse thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Combination therapy with ribavirin: Combination therapy with ribavirin is associated with birth defects and/or fetal mortality and hemolytic anemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Some formulations contain albumin, which may carry a remote risk of viral transmission, including a theoretical risk of Creutzfeldt-Jakob disease transmission.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product variability: <b>Due to differences in dosage, patients should not change brands of interferons without the concurrence of their health care provider. </b></p></div>
<div class="block prod-avail drugH1Div" id="F55869297"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">The manufacturer of Intron A, Merck, has made the decision to voluntarily discontinue the supply of all strengths of Intron A. Supplies of Intron A solution for injection are expected to be depleted around July 2021 and supplies of Intron A powder for reconstitution are expected to be depleted around March 2022.</p></div>
<div class="block foc drugH1Div" id="F183183"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intron A: 6,000,000 units/mL (3.8 mL [DSC]); 10,000,000 units/mL (3.2 mL [DSC]) [contains edetate (edta) disodium, metacresol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intron A: 10,000,000 units (1 ea [DSC]); 18,000,000 units (1 ea [DSC]); 50,000,000 units (1 ea [DSC]) [contains albumin human]</p></div>
<div class="block geq drugH1Div" id="F183168"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F2524635"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Intron A Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000000 unit (per each): $368.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50000000 unit (per each): $1,843.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867212"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intron A (Hsa-Free): 6,000,000 units/mL ([DSC]); 10,000,000 units/mL ([DSC]) [contains edetate (edta) disodium, metacresol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intron A: 10,000,000 units ([DSC])</p></div>
<div class="block adm drugH1Div" id="F183186"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer dose in the evening (if possible) to enhance tolerability. Not all dosage forms are recommended for all administration routes; refer to manufacturer's labeling. Interferon alfa-2b at doses ≥10 million units/m<sup>2</sup> is associated with a moderate emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>IM:</b> Rotate injection sites; preferred sites for injection are anterior thigh, deltoid, and superolateral buttock. Some patients may be appropriate for self-administration with appropriate training. Allow to reach room temperature prior to injection. In hairy cell leukemia treatment, if platelets are &lt;50,000/mm<sup>3</sup>, do not administer intramuscularly (administer SubQ instead).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over ~20 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SubQ:</b> Suggested for those who are at risk for bleeding or are thrombocytopenic. Rotate SubQ injection site; preferred sites for injection are abdomen (except around the navel), anterior thigh, and outer upper arm. Patient should be well hydrated. Some patients may be appropriate for self-administration with appropriate training. Allow to reach room temperature prior to injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intralesional:</b> Inject at an angle nearly parallel to the plane of the skin, directing the needle to center of the base of the wart to infiltrate the lesion core and cause a small wheal. Only infiltrate the keratinized layer; avoid administration which is too deep or shallow. Allow to reach room temperature prior to injection.</p></div>
<div class="block admp drugH1Div" id="F52613058"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Not all dosage forms are recommended for all administration routes; refer to manufacturer's labeling. Allow product to reach room temperature prior to injection.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer dose in the evening (if possible) to enhance tolerability. Rotate injection sites; preferred sites for injection are anterior thigh, deltoid, and superolateral buttock. Some patients may be appropriate for self-administration with appropriate training. In hairy cell leukemia treatment, if platelets are &lt;50,000/mm<sup>3</sup>, do not administer intramuscularly (administer SubQ instead).</p>
<p style="text-indent:-2em;margin-left:2em;">SubQ: Suggested for those who are at risk for bleeding or are thrombocytopenic. Rotate SubQ injection site; preferred sites for injection are abdomen (except around the navel), anterior thigh, and outer upper arm. Administer dose in the evening (if possible) to enhance tolerability. Patient should be well hydrated. Some patients may be appropriate for self-administration with appropriate training.</p></div>
<div class="block meg drugH1Div" id="F7874825"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F103132s5196lbl.pdf%23page%3D40&amp;token=q0FHzd2%2FRiWybw%2BC9pjVrsRPZBG1OMBWqPEP%2BKdwaCFA3EaJBJRSpmq6uAk3nNScHwHVcbQJfUiXgptYLMALaCxYd6sWyybT80WTx047XDSvwfNRXQaSTCB%2Fv8Yfkn7W&amp;TOPIC_ID=8563" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103132s5196lbl.pdf#page=40</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F183184"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>AIDS-related Kaposi sarcoma:</b> Treatment of AIDS-related Kaposi sarcoma in select patients ≥18 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis B:</b> Treatment of chronic hepatitis B in patients ≥1 year of age with compensated liver disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Condylomata acuminata:</b> Treatment of condylomata acuminata involving external surfaces of the genital and perianal areas in patients ≥18 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Follicular lymphoma:</b> Initial treatment of clinically aggressive follicular non-Hodgkin lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients ≥18 years of age. <b>Note:</b> Indications in the manufacturer's labeling may not reflect current clinical practices.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hairy cell leukemia:</b> Treatment of hairy cell leukemia in patients ≥18 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma (malignant):</b> Adjuvant to surgical treatment of malignant melanoma in patients ≥18 years of age who are free of disease but at high risk for systemic recurrence within 56 days of surgery. <b>Note:</b> High-dose interferon no longer has a defined role in the adjuvant treatment of cutaneous melanoma and is not recommended for routine adjuvant use (ASCO [Seth 2020]).</p></div>
<div class="block off-label drugH1Div" id="F25726543"><span class="drugH1">Use: Off-Label: Adult</span><p>Adult T-cell leukemia/lymphoma; Behçet syndrome (mucocutaneous ulcers); Chronic myeloid leukemia (alternate therapy in patients unable to take tyrosine kinase inhibitors); Cutaneous T-cell lymphomas (mycosis fungoides/Sézary syndrome); Desmoid tumors; Essential thrombocythemia (advanced); Myelofibrosis, early; Neuroendocrine tumors, GI carcinoid tumors (alternate therapy); Peyronie disease; Polycythemia vera (advanced); West Nile virus, neurologic symptoms</p></div>
<div class="block mst drugH1Div" id="F183238"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Interferon alfa-2b may be confused with interferon alfa-2a, interferon alfa-n3, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon beta-1a.</p>
<p style="text-indent:-2em;margin-left:4em;">Intron A may be confused with PEG-Intron.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Interferon alfa-2b may be confused with interferon alpha multi-subtype which is available in international markets.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F183220"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F183177"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.  Management: Consider using lower doses to minimize toxicity of this combination. Only coadminister aldesleukin and interferons (alfa) in patients in whom potential benefits outweigh the risk of severe toxicity. Monitor renal and cardiac function closely if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: Interferons (Alfa) may increase the serum concentration of Fluorouracil Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Interferons (Alfa) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Oral Inhalation): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Systemic): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telbivudine: Interferons (Alfa) may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk of peripheral neuropathy may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Interferons (Alfa) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307936"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to administration in females of reproductive potential. Disruption of the normal menstrual cycle may occur. Female patients of reproductive potential should use effective contraception during treatment.</p>
<p style="text-indent:0em;margin-top:2em;">If used in combination with ribavirin, all warnings related to the use of ribavirin and contraception should be followed. Refer to the Ribavirin monograph for additional information.</p></div>
<div class="block pri drugH1Div" id="F183191"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Alfa interferon is endogenous to normal amniotic fluid (Lebon 1982); however, placenta perfusion studies note exogenous interferon alfa does not cross the placenta (Waysbort 1993).</p>
<p style="text-indent:0em;margin-top:2em;">Essential thrombocythemia is associated with an increased risk of thrombosis, bleeding and, when untreated, may increase the risk of pregnancy loss. Maternal use of interferon alfas may improve pregnancy outcomes; use of interferon alfa-2b may be considered in pregnant women when other agents are not appropriate (Lapoirie 2020; Maze 2019; Sakai 2018; Tefferi 2019; Yazdani Brojeni 2012; Yoshida 2017).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology (ESMO) has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines suggest that interferon-alfa may be used for the treatment of chronic myeloid leukemia (CML) during pregnancy and recommend referral to a facility with expertise in cancer during pregnancy; a multidisciplinary team (obstetrician, neonatologist, oncology team) is encouraged (ESMO [Peccatori 2013]). An international consensus panel suggests use of interferon-alfa in pregnant patients once WBC and platelet counts have risen to a level associated with CML symptom onset (Lishner 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Interferon alfa-2b in combination with ribavirin is contraindicated in pregnant females and males whose female partners are pregnant. Combination therapy with ribavirin may cause birth defects and death in an unborn child. If used in combination with ribavirin, all warnings related to the use of ribavirin and pregnancy should be followed. Refer to the Ribavirin monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F183192"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Interferon alfa is endogenous to breast milk. Breast milk samples obtained from a lactating mother prior to and after administration of interferon alfa-2b showed that interferon alfa is present in breast milk and administration of the medication did not significantly affect endogenous levels (Kumar 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">If used in combination with ribavirin, all warnings related to the use of ribavirin and breastfeeding should be followed. Refer to the Ribavirin monograph for additional information.</p></div>
<div class="block mop drugH1Div" id="F183181"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">General monitoring parameters for <i>all indications</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">At baseline (repeat during therapy if clinically indicated): Chest x-ray, serum creatinine, albumin, prothrombin time, triglycerides.</p>
<p style="text-indent:-2em;margin-left:4em;">At baseline and periodically thereafter: CBC with differential, platelets and hemoglobin, liver function tests, electrolytes and TSH; ophthalmic exam (or with new ocular symptoms); ECG (in patients with pre-existing cardiac abnormalities or in advanced stages of cancer). Monitor serum bilirubin, ALT, AST, alkaline phosphatase and LDH at 2, 8 and 12 weeks following initiation, then every 6 months during treatment. Permanently discontinue for severe (grade 3) hepatic injury or hepatic decompensation (Child-Pugh class B and C [score &gt;6]).</p>
<p style="text-indent:-2em;margin-left:4em;">During therapy: Weight; neuropsychiatric changes during and for 6 months after therapy.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Additional <i>indication-specific</i> monitoring parameters:</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic hepatitis B: CBC with differential and platelets and liver function tests: Baseline, weeks 1, 2, 4, 8, 12, and 16, at the end of treatment, and then 3 and 6 months post treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Condyloma acuminate (intralesional administration): Monitor CBC with differential, liver function tests (elevations have been reported).</p>
<p style="text-indent:-2em;margin-left:4em;">Melanoma, malignant: CBC with differential and platelets and liver function tests: Weekly during induction phase, then monthly during maintenance.</p>
<p style="text-indent:-2em;margin-left:4em;">Oncology uses: Thyroid function monitoring (Hamnvik 2011): TSH and anti-TPO antibodies at baseline; if TPO antibody positive, monitor TSH every 2 months; if TPO antibody negative, monitor TSH every 6 months. Hepatitis B virus screening with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antibody to hepatitis B surface antigen (anti-HBs) prior to beginning systemic anticancer therapy (ASCO [Hwang 2020]).</p></div>
<div class="block pha drugH1Div" id="F183171"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferon alfas bind to a specific receptor on the cell membrane to initiate intracellular activity; multiple effects can be detected including induction of gene transcription. It inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells</p></div>
<div class="block phk drugH1Div" id="F183188"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 31 L; but has been noted to be much greater (370 to 720 L) in patients with leukemia receiving continuous infusion IFN; IFN does not penetrate the CSF.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily renal, filtered and absorbed at the renal tubule.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: IM: 83%; SubQ: 90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: ~2 hours; IM, SubQ: ~2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM, SubQ: ~3 to 12 hours; IV: By the end of a 30-minute infusion.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F183193"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bioferon | Inf | Inmutag | Interferon alfa 2b | Interimmun</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Realdiron</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alfainterferona 2b | Alfainterferona 2b (recombinante) | Blauferon b - interferon alfa-2b | Interferon | Intron a</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An da fen | Anferon | Anterferon | Interferon | Intron a | Kai yin yi sheng | Leferon | Long hua nuo | Reaferonum | Recombinant Human Interferon alfa 2b | Wan fu yin | Ying te long</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Heberon alfa R | Intron a | Introna</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alphaferon | Heberon alfa | Intron a</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Heberon alfa R | Introna</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Heberon alfa R | Intron a</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Egyferon | Intron a</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Introna | Viraferon</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Viraferon</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Introna</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Inarif-3 | Intron a | Realfa 2b | Zavinex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Introna</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alphaferon | Intron a</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bioferon | Intron a</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Realdiron</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Realdiron</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Viraferon</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Lemeron | Urifron alfa 2-b</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bioferon | Intron a</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Uniferon</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Anferon | Bioferon | Blauferon B | Ceron Alpha | Heberon-alpha r | Inf | Intron a | Laifulong | Leveron | Uniferon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bioferon | Inf | Interferon alfa 2b fusa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alfarona | Alpharona | Heberon alfa R | Interal p | Interferal | Interferon alfa 2b | Introna | Laferobion | Lifferon | Reaferon es | Realdiron | Recolin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Introna</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bioferon</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Intron a | Introna</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alfarekin | Alfiron | Bioferon | Introbion | Introna | Laferobion | Laferon | Realdiron</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bioferon | Blauferon B | Interferon alfa 2b</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Intron a</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28135150">
<a name="28135150"></a>Agarwala SS, Lee SJ, Yip W, et al. Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). <i>J Clin Oncol</i>. 2017;35(8):885-892.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/28135150/pubmed" id="28135150" target="_blank">28135150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15145269">
<a name="15145269"></a>Al Bahar S, Pandita R, Nath SV. Pregnancy in chronic myeloid leukemia patients treated with alpha interferon.<i> Int J Gynaecol Obstet.</i> 2004;85(3):281-282. doi: 10.1016/j.ijgo.2003.11.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/15145269/pubmed" id="15145269" target="_blank">15145269</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA). Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Updated October 5, 2021. Accessed May 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23803709">
<a name="23803709"></a>Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i>. 2013;122(6):872-884.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/23803709/pubmed" id="23803709" target="_blank">23803709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29515238">
<a name="29515238"></a>Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i>. 2018;32(5):1057-1069. doi:10.1038/s41375-018-0077-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/29515238/pubmed" id="29515238" target="_blank">29515238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20585095">
<a name="20585095"></a>Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. <i>J Clin Oncol.</i> 2010;28(27):4177-4183. doi: 10.1200/JCO.2010.28.0669.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/20585095/pubmed" id="20585095" target="_blank">20585095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21673346">
<a name="21673346"></a>Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. <i>Blood</i>. 2011;118(7):1736-1745. doi: 10.1182/blood-2011-03-345702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/21673346/pubmed" id="21673346" target="_blank">21673346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29447062">
<a name="29447062"></a>Berman E, Druker BJ, Burwick R. Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy. <i>J Clin Oncol.</i> 2018;36(12):1250-1256. doi: 10.1200/JCO.2017.77.2574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/29447062/pubmed" id="29447062" target="_blank">29447062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32808988">
<a name="32808988"></a>Dulek DE, Fuhlbrigge RC, Tribble AC, et al. Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute COVID-19 in pediatric patients. <i>J Pediatric Infect Dis Soc</i>. Published online August 18, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/32808988/pubmed" id="32808988" target="_blank">32808988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7760890">
<a name="7760890"></a>Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.<i> N Engl J Med.</i> 1995;332(26):1744-1748. doi: 10.1056/NEJM199506293322603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/7760890/pubmed" id="7760890" target="_blank">7760890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27903528">
<a name="27903528"></a>Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i>. 2017;129(5):553-560. doi: 10.1182/blood-2016-01-689422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/27903528/pubmed" id="27903528" target="_blank">27903528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010182">
<a name="22010182"></a>Hamnvik OP, Larsen PR, and Marqusee E, “Thyroid Dysfunction From Antineoplastic Agents,” <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/22010182/pubmed" id="22010182" target="_blank">22010182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7932420">
<a name="7932420"></a>Hamuryudan V, Moral F, Yurdakul S. Systemic interferon alpha 2b treatment in Behçet's syndrome. <i>J Rheumatol.</i> 1994;21(6):1098-1100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/7932420/pubmed" id="7932420" target="_blank">7932420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16753449">
<a name="16753449"></a>Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. <i>J Urol</i>. 2006;176(1):394-398. doi:10.1016/S0022-5347(06)00517-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/16753449/pubmed" id="16753449" target="_blank">16753449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12522449">
<a name="12522449"></a>Hermine O, Allard I, Lévy V, et al; French ATL therapy group. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. <i>Hematol J.</i> 2002;3(6):276-282. doi: 10.1038/sj.thj.6200195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/12522449/pubmed" id="12522449" target="_blank">12522449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22042945">
<a name="22042945"></a>Hodson A, Crichton S, Montoto S, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. <i>J Clin Oncol</i>. 2011;29(35):4696-4701. doi: 10.1200/JCO.2011.35.5578.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/22042945/pubmed" id="22042945" target="_blank">22042945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25069759">
<a name="25069759"></a>Huang BT, Zeng QC, Zhao WH, Li BS, Chen RL. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. <i>Leuk Res</i>. 2014;38(10):1177‐1183. doi:10.1016/j.leukres.2014.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/25069759/pubmed" id="25069759" target="_blank">25069759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25336628">
<a name="25336628"></a>Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. <i>Blood</i>. 2015;125(1):71-81. doi: 10.1182/blood-2014-07-588236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/25336628/pubmed" id="25336628" target="_blank">25336628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. Published online July 27, 2020. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Intron-A.1">
<a name="Intron-A.1"></a>Intron-A (interferon alfa-2b) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15714427">
<a name="15714427"></a>Kalil AC, Devetten MP, Singh S, et al. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. <i>Clin Infect Dis.</i> 2005;40(5):764-766. doi: 10.1086/427945.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/15714427/pubmed" id="15714427" target="_blank">15714427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19411628">
<a name="19411628"></a>Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). <i>Blood</i>. 2009;113(26):6528-6532. doi: 10.1182/blood-2009-03-211821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/19411628/pubmed" id="19411628" target="_blank">19411628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10856105">
<a name="10856105"></a>Kirkwood JM, Ibrahim JG, Sondak VK, et al, “High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190,” <i>J Clin Oncol</i>, 2000, 18(12):2444-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/10856105/pubmed" id="10856105" target="_blank">10856105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15079763">
<a name="15079763"></a>Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behçet disease: review of the literature. <i>Semin Arthritis Rheum.</i> 2004;33(5):320-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/15079763/pubmed" id="15079763" target="_blank">15079763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11153157">
<a name="11153157"></a>Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. <i>J Hum Lact</i>. 2000;16(3):226-228. doi: 10.1177/089033440001600308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/11153157/pubmed" id="11153157" target="_blank">11153157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9723590">
<a name="9723590"></a>Kuroiwa M, Gondo H, Ashida K, et al. Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy. <i>Am J Hematol.</i> 1998;59(1):101-102. doi: 10.1002/(sici)1096-8652(199809)59:1&lt;101::aid-ajh23&gt;3.0.co;2-d.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/9723590/pubmed" id="9723590" target="_blank">9723590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29945475">
<a name="29945475"></a>Lapoirie J, Contis A, Guy A, et al. Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms. <i>J Matern Fetal Neonatal Med</i>. 2020;33(1):49‐56. doi:10.1080/14767058.2018.1484097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/29945475/pubmed" id="29945475" target="_blank">29945475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6176680">
<a name="6176680"></a>Lebon P, Girard S, Thepot F, et al, “The Presence of Alpha-Interferon in Human Amniotic Fluid,” <i>J Gen Virol</i>, 1982, 59(Pt 2):393-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/6176680/pubmed" id="6176680" target="_blank">6176680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10649274">
<a name="10649274"></a>Leithner A, Schnack B, Katterschafka T, et al. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. <i>J Surg Oncol</i>. 2000;73(1):21-25. doi: 10.1002/(sici)1096-9098(200001)73:1&lt;21::aid-jso6&gt;3.0.co;2-g.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/10649274/pubmed" id="10649274" target="_blank">10649274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9119356">
<a name="9119356"></a>Lipton JH, Derzko CM, Curtis J. Alpha-interferon and pregnancy in a patient with CML.<i> Hematol Oncol</i>. 1996;14(3):119-122. doi: 10.1002/(SICI)1099-1069(199609)14:3&lt;119::AID-HON576&gt;3.0.CO;2-Q.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/9119356/pubmed" id="9119356" target="_blank">9119356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol</i>. 2016;34(5):501-508. doi: 10.1200/JCO.2015.62.4445.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11380470">
<a name="11380470"></a>Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients.<i> Br J Haematol.</i> 2001;113(3):779-784. doi: 10.1046/j.1365-2141.2001.02794.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/11380470/pubmed" id="11380470" target="_blank">11380470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31584685">
<a name="31584685"></a>Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis [published online October 2, 2019]. <i>JAMA Netw Open</i>. 2019;2(10):e1912666. doi:10.1001/jamanetworkopen.2019.12666<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/31584685/pubmed" id="31584685" target="_blank">31584685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30478826">
<a name="30478826"></a>McMullin MF, Harrison CN, Ali S, et al; BSH Committee. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. <i>Br J Haematol</i>. 2019;184(2):176-191. doi:10.1111/bjh.15648<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/30478826/pubmed" id="30478826" target="_blank">30478826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30932732">
<a name="30932732"></a>Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(14):1228-1263. doi: 10.1200/JCO.18.02096.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/30932732/pubmed" id="30932732" target="_blank">30932732</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://covid19treatmentguidelines.nih.gov/" target="_blank">https://covid19treatmentguidelines.nih.gov/</a>. Updated October 9, 2020. Accessed October 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26066402">
<a name="26066402"></a>Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's disease: AUA guideline. <i>J Urol</i>. 2015;194(3):745-753. doi:10.1016/j.juro.2015.05.098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/26066402/pubmed" id="26066402" target="_blank">26066402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14686708">
<a name="14686708"></a>Oberg K. Diagnosis and treatment of carcinoid tumors. <i>Expert Rev Anticancer Ther.</i> 2003;3(6):863-877. doi: 10.1586/14737140.3.6.863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/14686708/pubmed" id="14686708" target="_blank">14686708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14686974">
<a name="14686974"></a>Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. <i>Dermatol Ther</i>. 2003;16(4):311-321. doi: 10.1111/j.1396-0296.2003.01643.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/14686974/pubmed" id="14686974" target="_blank">14686974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23391116">
<a name="23391116"></a>Pavel M, Kidd M, Modlin I. Systemic therapeutic options for carcinoid. <i>Semin Oncol.</i> 2013;40(1):84-99. doi: 10.1053/j.seminoncol.2012.11.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/23391116/pubmed" id="23391116" target="_blank">23391116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi: 10.1002/pbc.27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170. doi: 10.1093/annonc/mdt199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19139440">
<a name="19139440"></a>Pectasides D, Dafni U, Bafaloukos D, et al, “Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma,” <i>J Clin Oncol</i>, 2009, 27(6):939-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/19139440/pubmed" id="19139440" target="_blank">19139440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31856918">
<a name="31856918"></a>Rini BI, Battle D, Figlin RA, etg al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). <i>J Immunother Cancer</i>. 2019;7(1):354. doi: 10.1186/s40425-019-0813-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/31856918/pubmed" id="31856918" target="_blank">31856918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16000130">
<a name="16000130"></a>Rupoli S, Goteri G, Pulini S, et al; Marche Regional Multicentric Study Group of Cutaneous Lymphomas. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides.<i> Eur J Haematol.</i> 2005;75(2):136-145. doi: 10.1111/j.1600-0609.2005.00497.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/16000130/pubmed" id="16000130" target="_blank">16000130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29290077">
<a name="29290077"></a>Sakai K, Ueda A, Hasegawa M, Ueda Y. Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review. <i>Int J Hematol</i>. 2018;108(2):203‐207. doi:10.1007/s12185-017-2397-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/29290077/pubmed" id="29290077" target="_blank">29290077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15198443">
<a name="15198443"></a>Sayao AL, Suchowersky O, Al-Khathaami A, et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. <i>Can J Neurol Sci.</i> 2004;31(2):194-203. doi: 10.1017/s031716710005383x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/15198443/pubmed" id="15198443" target="_blank">15198443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32228358">
<a name="32228358"></a>Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(33):3947-3970. doi:10.1200/JCO.20.00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/32228358/pubmed" id="32228358" target="_blank">32228358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9586886">
<a name="9586886"></a>Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. <i>J Clin Oncol</i>. 1998;16(5):1736-1742. doi: 10.1200/JCO.1998.16.5.1736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/9586886/pubmed" id="9586886" target="_blank">9586886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28518222">
<a name="28518222"></a>Silver RT, Barel AC, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. <i>Cancer</i>. 2017;123(14):2680‐2687. doi:10.1002/cncr.30679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/28518222/pubmed" id="28518222" target="_blank">28518222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26144333">
<a name="26144333"></a>Stewart CA, Yafi FA, Knoedler M, et al. Intralesional injection of interferon-α2b improves penile curvature in men with Peyronie's disease independent of plaque location. <i>J Urol</i>. 2015;194(6):1704-1707. doi: 10.1016/j.juro.2015.06.096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/26144333/pubmed" id="26144333" target="_blank">26144333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31774958">
<a name="31774958"></a>Tefferi A, Pardanani A. Essential thrombocythemia. <i>N Engl J Med</i>. 2019;381(22):2135‐2144. doi:10.1056/NEJMcp1816082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/31774958/pubmed" id="31774958" target="_blank">31774958</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. December 2016. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242182">
<a name="26242182"></a>Vannucchi AM, Barbui T, Cervantes F, et al; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2015;26(suppl 5):v85-v99. doi:10.1093/annonc/mdv203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/26242182/pubmed" id="26242182" target="_blank">26242182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8328774">
<a name="8328774"></a>Waysbort A, Giroux M, Mansat V, et al, “Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,” <i>Antimicrob Agents Chemother</i>, 1993, 37(6):1232-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/8328774/pubmed" id="8328774" target="_blank">8328774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27151889">
<a name="27151889"></a>Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. <i>Blood</i>. 2016;127(25):3142-3153. doi: 10.1182/blood-2015-12-611830.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/27151889/pubmed" id="27151889" target="_blank">27151889</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis c virus infection. https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1. Published July 2018. Accessed April 29, 2019.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015. <a href="https://www.ncbi.nlm.nih.gov/books/NBK305553/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK305553/</a>. Published March 2015. Accessed September 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22200624">
<a name="22200624"></a>Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. A systematic review of the fetal safety of interferon alpha. <i>Reprod Toxicol</i>. 2012;33(3):265‐268. doi:10.1016/j.reprotox.2011.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/22200624/pubmed" id="22200624" target="_blank">22200624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28194492">
<a name="28194492"></a>Yoshida Y, Katsurada T, Nakabou Y, Kawabata H. Efficacy of interferon-alpha in essential thrombocythemia during pregnancy. <i>Ann Hematol</i>. 2017;96(5):877‐878. doi:10.1007/s00277-017-2946-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/interferon-alfa-2b-united-states-and-canada-not-available-drug-information/abstract-text/28194492/pubmed" id="28194492" target="_blank">28194492</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8563 Version 282.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
